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Abstract
Background: Polycystic ovary syndrome (PCOS) is characterized by the growth of a number of small cysts on the
ovaries which leads to sex hormonal imbalance. Women who are affected by this syndrome suffer from irregular
menstrual cycles, decline in their fertility, excessive hair growth, obesity, acne and most importantly cardiac function
problems. The vascular endothelial growth factor (VEGF) plays a pivotal role in tissue vascularization in general and
in the pathogenesis of many diseases. The PCOS was found to be associated with high expression levels of VEGF. In
women who undergo assisted reproductive procedures (ART), VEGF was found to be a key mediator of other
factors to control ovary angiogenesis. Here, we set out to examine the association of VEGFA gene polymorphism
with PCOS and its components in a population of Tunisia women to enhance our understanding of the genetic
background leading angiogenesis and vascularization abnormalities in PCOS.
Methods: The association of VEGFA gene with PCOS and its components was examined in a cohort of 268 women
from Tunisia involving 118 PCOS patients and 150 controls. VEGFA gene variations were assessed through the
analysis of the following SNPs rs699947 (A/C), rs833061 (C/T), rs1570360 (G/A), rs833068 (G/A), rs3025020 (C/T), and
rs3025039 (C/T). The linkage disequilibrium between SNPs was assessed using HAPLOVIEW software while
combination of SNPs into haplotypes in the population and the reconstruction of the cladogram were carried-out
by PHASE and ARLEQUIN programs, respectively. Genetic association and genotype-phenotype correlations were
calculated by logistic regression and non-parametric tests (Kruskall-Wallis and Mann–Whitney tests), respectively,
using StatView program.
Results: We observed 10 haplotypes in our studied cohort whereH1 (ACGG), H2 (ACAG), H7 (CTGG) and H8 (CTGA)
were the most frequent. We observed the association of the genotype CT of the SNP rs30225039 with PCOS
phenotype (P = 0.03; OR 95 % CI = 2.05 [1.07–3.90]) and a trend for correlation of the pair of haplotypes H2/H2 with
prolactin levels in plasma (P = 0.077; 193.5 ± 94.3 vs 45.7 ± 7.2). These data are consistent with literature and
highlight one more time the role of vascularization in the pathogeny of PCOS.
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Conclusions: LD pattern in VEGF locus showed a similar LD pattern between the Tunisian population and the CEU.
More haplotypes in the Tunisian population than in CEU was observed (22 haplotypes vs 16 haplotypes) suggesting
higher recombination rate in Tunisians. The study showed that there was any advantage of using haplotypes
compared with SNPs taken alone.
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Background
The polycystic ovary syndrome (PCOS) is a disease af-
fecting 6 – 12 % of women at reproductive age and char-
acterized by abnormalities in relation to reproduction,
hyperandrogenism as well as metabolic abnormalities
like insulin resistance, obesity, impaired fasting glucose
(IGF) and metabolic syndrome (MetS) [1, 2].
Knowing the role of blood flow and vascular pattern
of an organ in the organ’s morphology and function, pre-
vious studies focused on the comparison of blood flow
and vascularization between women with PCOS and
healthy women showing larger and more vascularized
ovaries in PCOS women compared to the control [3].
Moreover, abnormalities in ovarian angiogenesis were
involved in the ovarian hyperstimulation syndrome
(OHSS) and other disorders of anovulation, subfertility
and pathogenic conditions as endometriosis [4]. In this
context, the vascular endothelial growth factor (VEGF)
system, composed of ligands and receptors plays a piv-
otal role in tissue vascularization and endothelial cell
growth [5]. It was also reported to induce cell prolifera-
tion, promote cell migration, inhibit apoptosis and in-
duce permeabilization of blood vessels. It is a major
component of the family of angiogenic factors, which in-
cludes placental growth factor, angiopoetin, basic fibro-
blast growth factor and the VEGF family (A, B, C, D and
E). VEGFA in particular is a protein encoded by a gene
(Gene ID: 7422) located in chromosome 6 and extended
on more than 16 kb (GRCh37/hg19; chr6: 43737946–
43754224). The gene involves 8 exons and encodes for
many VEGFA isoforms as VEGF-165 and VEGF-145.
Previous studies reported the association of VEGFA
gene with PCOS through SNPs +9812, +13553, −2578
(rs699947), −460 (rs833061) and +405 [6, 7] and their
haplotypes in populations of different origins [6–8].
Moreover, SNPs +405 and −460 were reported as having
a trend towards higher insulin resistance [9]. It was sug-
gested the role of some of these SNPs on the regulation
of VEGFA gene expression and protein production and
secretion [10].
In this context, we focused on the study of the associ-
ation of VEGFA gene with PCOS and its components in
a population of women from Tunisia well characterized
at the phenotypic level. The aim was to better
characterize the genetic background responsible for
angiogenesis and vascularization abnormalities in PCOS.
This will be achieved through testing the association of
VEGFA gene in a population where it was previously
highlighted the need for haplotyping approach in order
to understand better the genetic association in popula-
tions with mosaic anthropogenetic components [11, 12].
Subjects and methods
1. Subjects
Following an informed consent, a total of 268
unrelated Tunisian women, consisting of 118 PCOS
patients and 150 controls. PCOS patients group
(mean age: 29.8 ± 0.4 years) were recruited from the
outpatient Obstetrics and Gynecology Department,
CHU Farhat Hached (Sousse) in Central Tunisia
(Table 2). The diagnosis of PCOS was based on the
2003 Rotterdam Criteria [13]. PCOS was then
attested when two of the following three conditions
are observed: anovulation, hyperandrogenism, and
the presence of polycystic ovaries on ultrasound
examination. Exclusion criteria were androgen-
producing tumors, 21-hydroxylase-deficiency, non-
classical adrenal hyperplasia, hyperprolactinemia,
active thyroid disease, and Cushing’s syndrome.
Control group consisted of 150 healthy women
(mean age: 33.5 ± 0.5 years), with regular menstrual
cycles and no evidence of hirsutism, acne, alopecia,
or endocrinopathies. None of the controls was on
hormonal therapy (including oral contraceptives) for
the previous three months or longer, and none of
PCOS women or controls was on medication known
to affect carbohydrate metabolism or endocrine
parameters, at least for the last three months before
inclusion in the study. Demographic data and
history of hypertension, diabetes, and
hypercholesterolemia were recorded for all subjects.
Obesity was defined as body-mass index (BMI)
≥30 kg/m2. The protocol of the study was approved
by the local ethics committee, and written informed
consent was obtained from all subjects.
2. SNPs genotyping
Total genomic DNA was isolated from peripheral
blood lymphocytes by the salting-out method. Six
SNPs were selected because of their association with
PCOS, angiogenesis and other metabolic components
in literature: rs699947 (A/C), rs833061 (C/T),
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rs1570360 (G/A), rs833068 (G/A), rs3025020 (C/T),
andrs3025039 (C/T). The 6 SNPs were genotyped by
the allelic discrimination TaqMan SNP Genotyping
Assays (Applied Biosystems; Foster City, CA). The PCR
primers and TaqManprobes were directly available
from Applied Biosystem (predesigned assays) and ana-
lyses were done according to the manufacturer’s
protocol on a StepOne plus apparatus (Applied Bio-
systems) (Table 1).
Statistical analysis
Data were expressed as mean ± SE (continuous variables)
or as percent of total (categorical variables), and inter-
group significance was assessed by χ2 test. Allele frequen-
cies were calculated by gene-counting method; each SNP
was tested for Hardy–Weinberg equilibrium using Haplo-
view 4.2 (http://www.broadinstitute.org/haploview). Link-
age disequilibrium (LD) was assessed using Haploview 4.2.
Genetic association and genotype-phenotype correlation
were assessed by logistic regression and non-parametric
tests (Mann–Whitney and Kruskall-Walli tests) using
StatView program.




Women with PCOS have higher BMI than controls (P <
0.0001; 28.4 ± 0.7 vs 23.1 ± 0.2 kg/m2), higher random gly-
cemia (P <0.0001, 7.9 ± 0.2 vs 4.5 ± 0.1 mmol/L), fasting
insulin (P = 0.01, 15.7 ± 1.2vs 7.7 ± 0.4 mU/L), levels of
total testosterone (P < 0.0001, 2.9 ± 0.2 vs 1.0 ± 0.1 noml/
L) and of plasma triglycerides (TG) (P = 0.0001, 1.7 ± 0.1
vs 1.0 ± 0.1). Prolactin levels in plasma were lower in
women with PCOS compared with controls (P = 0.0001,
73.1 ± 11.7 vs 148.8 ± 9.4) (Table 2).
Genotype data
All SNPs were in Hardy-Weinberg equilibrium. Allele
frequencies of SNPs in PCOS and controls were respect-
ively0.56 and 0.56 for rs699947, 0.51 and 0.54 for
rs833061, 0.34 and 0.31 for rs1570360, 0.37 and 0.36 for
rs833068, 0.25 and 0.22 for rs3025020 and 0.87 and 0.91
for rs3025039 (Table 3).
The study of LD pattern (assessed by D’ index) in the
region delimited by these SNPs showed relative high LD
between SNPs rs699947, rs833061, rs1570360 and
rs833068 (Fig. 1) allowing then reconstruction of haplo-
types with these 4 polymorphisms. We observed 10 hap-
lotypes among which 4 haplotypes were the most
frequent: H1 (ACGG)(13.4 %), H2 (ACAG) (29.3 %), H7
(CTGG) (19.6 %) and H8 (CTGA) (32.3 %)(Table 4).
Reconstruction of the cladogram in the population
allowed observing that H2 arose from H1 after the mu-
tation of the SNP r1570360 while H7 appeared after the
mutation of rs1570360, rs833061 and rs699947. Finally,
H8 arose after the mutation of rs1570360, rs833061,
rs699947 and rs833068 (Fig. 2).
Logistic regression showed the association of the geno-
type CT of rs30225039 with PCOS phenotype (P = 0.03;
OR 95 % CI = 2.05 [1.07 – 3.90]) (Table 5) while non-Table 1 SNPs probe sequence




















Age (years) 29.8 ± 0.4 33.5 ± 0.5 <0.0001
BMI (kg/m2) 28.4 ± 0.7 23.1 ± 0.2 <0.0001
Random glycemia (mmol/L) 7.9 ± 0.2 4.5 ± 0.1 <0.0001
Fasting insulin (mU/L) 15.7 ± 1.2 7.7 ± 0.4 0.01
Testosterone (nmol/L) 2.9 ± 0.2 1.0 ± 0.1 <0.0001
Prolactin (mU/L) 73.1 ± 11.7 148.8 ± 9.4 0.0001
Triglycerides (mmol/L) 1.7 ± 0.1 1.0 ± 0.1 0.0001
LDL cholesterol 3.1 ± 0.1 1.9 ± 0.2 <0.0001
MetS ATPIII (%) 34.7 0.0 <0.0001
aThe significance of the difference between cases and controls is assessed by
X2 test





rs699947 43736389 A 0.56 0.56 0.873
rs833061 43737486 C 0.51 0.54 0.656
rs1570360 43737830 A 0.34 0.31 0.520
rs833068 43742527 A 0.37 0.36 0.820
rs3025020 43749110 T 0.25 0.22 0.403
rs3025039 43752536 C 0.87 0.91 0.126
aPearson’s chi square test
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parametric tests allowed observing a trend for correl-
ation of the pair of haplotypes H2/H2 to prolactin levels
in plasma (P = 0.077; 193.5 ± 94.3 vs 45.7 ± 7.2). Accord-
ing to the calculation, this study had a power of
58.38 %. PCOS is a disease that affects women at
reproductive age and characterized by endocrine dis-
orders as menses disturbance and subfertility and by
metabolic abnormalities as insulin resistance, and
glucose intolerance [14, 15]. Angiogenesis process has
also been reported as probably implied in disorders of
anovulation, subfertility and other pathogenic condi-
tions as endometriosis. Since VEGF system plays a
pivotal role in tissue vascularization, VEGFA gene is
considered as candidate in reproductive abnormalities
Fig. 1 Linkage disequilibrium (LD) pattern in the locus of VEGFA gene
delimited by SNPs rs699947 and rs3025039. Numbers in the squares
indicate D’ index (level of LD) between the corresponding SNPs
Fig. 2 Cladistic representation of VEGFA haplotypes in the studied population. SNPs mutations responsible for the transition between haplotypes
are indicated in the cladogram. H1 is the ancestral haplotype
Table 4 List of haplotypes resulting from the combination of













H1 A C G G 13.4 0.749
H2 A C A G 29.3 0.595
H3 A C A A 0.9 0.021
H4 A T A G 0.4 0.081
H5 C C G G 0.2 0.059
H6 C C G A 2.1 0.781
H7 C T G G 19.6 0.725
H8 C T G A 32.3 0.389
H9 C T A G 0.4 0.068
H10 C T A A 1.5 0.088
H1 is the ancestral haplotype (haplotype of chimpanzee: Pan troglodytes)
P (χ2) indicates the significance of variability of each polymorphism between
the two groups
NS not statistically significant
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as PCOS. Many studies have been carried-out and
concluded in a part of them that VEGFA levels in
serum or follicular fluid are higher in women with
PCOS [16–19]. In another hand, previous studies in
Korean and Turkish populations reported the associ-
ation of VEGFA gene with PCOS through many SNPs
and one haplotype [6–8]. In that context, our investi-
gation focused on the study of VEGFA gene associ-
ation with PCOS in a Tunisian population well
characterized at the phenotypic level, through 6 SNPs
and their combination into haplotypes in the popula-
tion. We observed the association of the gene (SNP
rs30225039) with PCOS phenotype and a trend of
correlation (pair of haplotypes H2/H2) with prolactin
levels in plasma. Prolactin is secreted mainly by the
pituitary gland and is implied in many processes as
lactation and also tissue vascularization [20]. Indeed,
many studies showed the role of prolactin as a pro-
angiogenic factor while its enzymatically cleaved
16 kDa N-terminal fragment has a well-defined anti-
angiogenic effect [21]. Moreover, it was shown the ef-
fect of prolactin on the induction of VEGF expression
[22–24]. To the best of our knowledge, our study is
the first work that reports the correlation, even with
a trend, of VEGFA gene variations with prolactin
plasma levels. These findings suggest possible regula-
tion and/or feedback control of prolactin secretion
pathway through VEGF and the role of VEGFA gene
variation in this process. Deeper genetic investigations
taking into account more SNPs and larger locus are
necessary to demystify these molecular pathways.
Differences of VEGF plasma levels between PCOS and
healthy women were observed in some populations but
not in others and this could be due to genetic differences
between ethnic groups [16–19] Studying VEGFA gene
association in complex disorders should take into ac-
count the gene variability in the population through the
LD pattern assessment and SNPs combination into hap-
lotypes. We reported in a previous study the role of
haplotypes as powerful genetic markers for better
characterization of gene association in the Tunisian
population and observed Fat mass and obesity associated
(FTO) gene association with PCOS through haplotypes
but not through SNPs taken alone [12]. Indeed, we
Table 5 Distribution of VEGF genotype in PCOS cases and
control women
1/1a 1/2a 2/2a
PCOS Controls PCOS Controls PCOS Controls P
rs699947 0.3b 0.3 0.53 0.51 0.17 0.19 0.65
rs833061 0.28 0.28 0.46 0.51 0.25 0.21 0.38
rs1570360 0.48 0.5 0.36 0.38 0.16 0.12 0.71
rs833068 0.36 0.43 0.53 0.42 0.11 0.15 0.09
rs3025020 0.58 0.6 0.34 0.35 0.08 0.05 0.38
rs3025039 0.75 0.85 0.23 0.13 0.02 0.03 0.03
aGenotypes were coded as per “1” =major allele, “2” =minor allele
bFrequency
Fig. 3 Comparison of linkage disequilibrium (LD) pattern (LD is assessed by r2 index) in the VEGF locus delimited between SNPs rs699947 and
rs3025039, between the studied women population and the CEU reference population. Numbers in the squares indicates levels of LD as
informed by r2 index
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observed LD pattern in the FTO locus less in the Tunis-
ian population compared with the CEU Caucasian one
justifying so the ability of haplotypes for detecting gen-
etic association in such conditions. In the present study,
the investigation of the LD pattern in VEGF locus
showed a similar LD pattern between the Tunisian
population and the CEU one (Fig. 3). However, we found
more haplotypes in the Tunisian population than in
CEU (22 haplotypes vs 16 haplotypes) suggesting more
recombination rate operated in Tunisians. Although we
were not able to observe any advantage of using haplo-
types compared with SNPs taken alone in this study,
these results could suggest a more complex anthropoge-
netics context concerning VEGF locus or the need for a
better characterization of this locus by using more dens-
ity of SNPs at larger genomic region/scale and using lar-
ger cohorts of patients. Therefore, better management
approaches can be identified [25]. Additionally, and des-
pite the relatively reduced size of our cohort, it remains
that the powering of the study was acceptable (58.38 %)
attesting then for the reliability of our findings.
Conclusions
Deeper investigations of VEGFA gene encompassing lar-
ger regions in the locus and using more SNPs need to be
envisioned in order to better characterize the gene associ-
ation in the Tunisian population and to shed light on the
genetic/genomic players involved and develop better diag-
nostic, management and therapeutic approaches.
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